Literature DB >> 22994971

Guidelines for the investigation and management of mantle cell lymphoma.

P McKay1, M Leach, R Jackson, G Cook, S Rule.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22994971     DOI： 10.1111/bjh.12046

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  21 in total

1.  High-grade GI lymphoma presenting with diarrhoea.

Authors:  Sinan Al-Rubaye; Sophie Henson; Ali Mahdi
Journal:  BMJ Case Rep       Date:  2013-06-05

2.  Blastoid Variant of Mantle Cell Lymphoma with Leukemic Presentation - A Rare Case Report.

Authors:  Ruchee Khanna; Sushma Belurkar; P Lavanya; Chethan Manohar; Manna Valiathan
Journal:  J Clin Diagn Res       Date:  2017-04-01

3.  The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.

Authors:  S Robinson; P Dreger; D Caballero; P Corradini; C Geisler; M Ghielmini; S Le Gouill; E Kimby; S Rule; U Vitolo; M Dreyling; O Hermine
Journal:  Leukemia       Date:  2014-07-18       Impact factor: 11.528

4.  Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.

Authors:  Thomas E Witzig; Pier Luigi Zinzani; Thomas M Habermann; Joseph M Tuscano; Johannes Drach; Radhakrishnan Ramchandren; Sevgi Kalayoglu Besisik; Kenichi Takeshita; Marie-Laure Casadebaig Bravo; Lei Zhang; Tommy Fu; Andre Goy
Journal:  Am J Hematol       Date:  2017-08-28       Impact factor: 10.047

5.  Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Authors:  Andre Goy; Rajni Sinha; Michael E Williams; Sevgi Kalayoglu Besisik; Johannes Drach; Radhakrishnan Ramchandren; Lei Zhang; Sherri Cicero; Tommy Fu; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

Review 6.  Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.

Authors:  Esther S Kim; Sohita Dhillon
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

7.  Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.

Authors:  Peter A Riedell; Mehdi Hamadani; Kwang W Ahn; Carlos Litovich; Guru Subramanian Guru Murthy; Frederick L Locke; Claudio G Brunstein; Reid W Merryman; Patrick J Stiff; Attaphol Pawarode; Taiga Nishihori; Mohamed A Kharfan-Dabaja; Alex F Herrera; Craig S Sauter; Sonali M Smith
Journal:  Transplant Cell Ther       Date:  2021-08-24

Review 8.  Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Paul Tappenden; Emma Simpson; Jean Hamilton; Daniel Pollard; Mark Clowes; Eva Kaltenthaler; David Meiklejohn; Nick Morley
Journal:  Pharmacoeconomics       Date:  2019-03       Impact factor: 4.981

9.  Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.

Authors:  P L Zinzani; J M Vose; M S Czuczman; C B Reeder; C Haioun; J Polikoff; H Tilly; L Zhang; K Prandi; J Li; T E Witzig
Journal:  Ann Oncol       Date:  2013-09-12       Impact factor: 32.976

10.  Lymphoma without Lymphadenopathy.

Authors:  Ashutosh Jain; Nilesh Kumar; Mahendra K Jangid; Indrajeet Singh Gambhir; Vijai Tilak
Journal:  Chin Med J (Engl)       Date:  2015-12-05       Impact factor: 2.628
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.